New oral anticoagulants in thrombotic antiphospholipid syndrome

Lupus

Volumn 23, Issue 12, 2014, Pages 1279-1282

  Chighizola, C B ^a,b   Moia, M ^c   Meroni, P L ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

anticoagulation; Antiphospholipid syndrome; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DIRECT ORAL ANTICOAGULANT; EDOXABAN; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; FOOD DRUG INTERACTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE TOXICITY; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS; ANTAGONISTS AND INHIBITORS; COMPLICATION; FEMALE; ORAL DRUG ADMINISTRATION; PREGNANCY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; THROMBOSIS; VITAMIN K;

EID: 84908671635     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314540968     Document Type: Conference Paper

References (10)

1. Miyakis S, Lockshin MD, Atsumi M, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
2. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus. 2011 ; 20: 206-218
3. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010 ; 8: 237-242
4. Cervera R, Serrano R, Pons-Estel GR, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2014 Jan 24; doi:10.1136.
5. Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep. 2013 ; 15: 331-339
6. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: The new anticoagulants?. Lupus. 2010 ; 19: 486-491
7. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007 ; 57: 1487-1495
8. Danza A, Ruiz-Irastorza G, Khamashta MA. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012 ; 26: 65-76
9. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol. 2011 ; 7: 330-339
10. Erkan D, Aguiar CL, Andrade D, et al. 14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014 ; 13: 685-696